AstraZeneca’s COVID-19 vaccine data fails to impress Wall Street analysts with its effectiveness in clinical trials

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 65 sec. here
  • 3 min. at publisher
  • 📊 Qulity Score:
  • News: 29%
  • Publisher: 97%

The average efficacy rate for AstraZeneca's vaccine candidate is significantly lower than the roughly 95% efficacy rates reported last week for BioNTech and Pfizer’s and Moderna's.

United States Headlines News

United States Latest News, United States Headlines

AstraZeneca’s experimental COVID-19 vaccine is the third vaccine to demonstrate it can prevent coronavirus infections in a late-stage clinical trial, though the viral vector-based vaccine is much less efficacious than the other leading vaccine candidates.

The British drug maker, which is developing the vaccine with the University of Oxford, said the vaccine had an efficacy rate of 90% in a small subset of about 2,700 participants in Brazil and the U.K. who received a half dose and then a full dose four weeks later, according to an interim analysis. A larger group of nearly 8,900 participants produced an efficacy rate of 62% when given two full doses, spaced a month apart.

AstraZeneca’s decision to include two efficacy rates was criticized by one Wall Street analyst as insufficient. However, the inclusion of the smaller subset with a higher efficacy rate may indicate a company strategy to push this vaccine to markets in less developed countries. They “are clearly already positioning the product as suitable for use in less developed countries, where their relatively favorable storage conditions...

An mRNA vaccine has never received any type of regulatory approval, and the ones being tested right now have refrigeration requirements that will likely impact how easily a vaccine can be distributed. Viral vector-based vaccines, like AstraZeneca’s ChAdOx1 and Johnson & Johnson’s JNJ, -1.01% Ebola virus vaccine, have been around for decades and do not have the same level of cold-storage requirements.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in US
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

worth noting that AstraZeneca's C19 vaccine is not on a RNA based platform

I guess production capacity needed to vaccinate global population. I see a big demand, irrelevant to efficacy. Ramp up or generics take your demand.

The average efficacy rate for COVID19 vaccine is not better than 1-5% (based on % of recovery without any vaccination), and can go down to 0%! All coronavirus vaccines are self-proclaimed and without any scientific or clinical proof that can be trusted. The BIGGEST SCAM!

Similar News:You can also read news stories similar to this one that we have collected from other news sources.